(Q21144660)

16 August 2022

Jacques H

Grosset

Jacques H Grosset

1 reference

16 August 2022

Eric L

Nuermberger

Eric L Nuermberger

1 reference

16 August 2022

Ian M Rosenthal

Ian M

Rosenthal

1 reference

16 August 2022

Ming Zhang

Ming

Zhang

1 reference

16 August 2022

Kathy N Williams

Kathy N

Williams

1 reference

16 August 2022

Charles A Peloquin

Charles A

Peloquin

1 reference

16 August 2022

Sandeep Tyagi

Sandeep

Tyagi

1 reference

16 August 2022

Andrew A Vernon

Andrew A

Vernon

1 reference

16 August 2022

William R Bishai

William R

Bishai

1 reference

Creative Commons CC0 License

16 August 2022

language of work or name

English

0 references

publication date

December 2007

0 references

0 references

0 references

0 references

e344

0 references

start time

18 December 2007

1 reference

April 2022 Public Data File from Crossref

copyrighted, dedicated to the public domain by copyright holder

0 references

cites work

Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Potentially Serious Side Effects of High-dose Twice-weekly Rifampicin

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Adverse Effects of Rifampin

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Tuberculosis drug development pipeline: progress and hope

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Reassuring safety profile of moxifloxacin

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2140085

Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore

29 November 2018

1 reference

12 December 2020

Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report

1 reference

12 December 2020

Development of rifapentine: the way ahead

1 reference

12 December 2020

A nested case-control study on treatment-related risk factors for early relapse of tuberculosis

1 reference

12 December 2020

In the treatment of tuberculosis, you get what you pay for...

1 reference

12 December 2020

Once upon a time. . . improved intermittent therapy for tuberculosis--fact or fable?

1 reference

12 December 2020

Medicine. A portfolio model of drug development for tuberculosis

1 reference

12 December 2020

10.1371/JOURNAL.PMED.0040344

Identifiers

DOI

1 reference

1 reference

1 reference

1 reference